Literature DB >> 320828

Comparative clinical evaluation of lofepramine and imipramine. Pharmacological aspects.

B Siwers, S Borg, G d'Elia, G Lundin, G P Forshell, H Raotma, G Román.   

Abstract

A multicentre comparative clinical evaluation of lofepramine, an imipramine analogue, and imipramine has been made with double-blind technique and fixed dosage (lofepramine 70 mg t.i.d., imipramine 50 mg t.i.d.). Plasma was drawn after 3 weeks for determination of noradrenaline-uptake inhibitory capacity of the parent compound and/or its active metabolites. Plasma concentrations of lofepramine and desmethylimipramine (DMI) were determined in the same samples. The concentrations of lofepramine in the whole material were low (5-27 ng/ml) except for one patient who had a level of 53 ng/ml. In both groups of patients there was an almost 40-fold range in the plasma levels of DMI or apparent DMI. The patients were rated for severity of depression before treatment, then once weekly for 3 weeks and finally during the fifth week. For further information concerning the psychiatric aspects, see d'Elia et al. in this issue (1977). A significant correlation was found between the concentrations of DMI and the noradrenaline-uptake inhibitory capacity in the plasma samples. No correlations were found between uptake inhibitory capacity of plasma samples and the amelioration scores.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 320828     DOI: 10.1111/j.1600-0447.1977.tb00137.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  3 in total

Review 1.  Plasma level monitoring of tricyclic antidepressant therapy.

Authors:  L F Gram
Journal:  Clin Pharmacokinet       Date:  1977 Jul-Aug       Impact factor: 6.447

Review 2.  Centrally acting drugs.

Authors:  D N Bateman; S Chaplin
Journal:  Br Med J (Clin Res Ed)       Date:  1988-02-06

Review 3.  Lofepramine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.

Authors:  S G Lancaster; J P Gonzalez
Journal:  Drugs       Date:  1989-02       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.